Cullinan Therapeutics

graphic image of a cube with an arrow nailing the bullseye
Biotech

ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC

The companies plan to submit the EGFR tyrosine kinase inhibitor for an FDA approval during the second half of this year.
Gabrielle Masson May 22, 2025 5:00pm
start line beginning road path starting point journey

Cullinan CEO sets tone for bispecific's upcoming lupus readout

Feb 7, 2025 5:00am
On target clinical trial success bullseye score

Cullinan plans approval push for NSCLC drug after ph. 2 win

Jan 29, 2025 6:15am
Deal terminate tear up end deal scrap

Cullinan, after $25M deal, hands back bispecific to Harbour

Aug 8, 2024 10:10am
Graphic image of a compass above an unfolded map Orange background color

Cullinan rebrands, halts lymphoma trial in autoimmune refocus

Apr 16, 2024 10:05am
Photo of five sailboats setting out in the same direction over dark blue water

Cullinan plucks US rights to Harbour BioMed's novel bispecific

Feb 13, 2023 7:00pm